MedTrace Logo

A Liquid Biopsy for High-risk Pre-cancer Screening of Esophageal Adenocarcinoma

NCT06381583 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 658

Last updated 2024-05-10

No results posted yet for this study

Summary

This study aims to develop a highly sensitive, specific, and cost-effective blood assay for the early detection of esophageal adenocarcinoma and its precursor lesions, using advanced machine learning and state-of-the-art biological analyses.

Conditions

  • Esophagus Cancer
  • Esophageal Cancer Stage
  • Esophageal Cancer
  • Esophageal Neoplasms
  • Esophagus Adenocarcinoma
  • Esophagus, Barrett
  • Barrett Esophagus
  • Barrett Adenocarcinoma
  • Barrett Epithelium
  • Barretts Esophagus With Dysplasia
  • Barrett's Esophagus Without Dysplasia
  • Barretts Esophagus With High Grade Dysplasia
  • Barretts Esophagus With Low Grade Dysplasia
  • Barrett Esophagus, Long-Segment
  • Barrett's Esophagus With Dysplasia, Unspecified
  • Barrett's Esophagus With Esophagitis
  • Gastroesophageal Reflux
  • Reflux Disease
  • Esophageal Adenocarcinoma
  • Esophageal Dysplasia
  • Esophageal Neoplasms Malignant

Interventions

DIAGNOSTIC_TEST

EMERALD (Esophageal MicroRNAs for BaRRett's esophagus, Adenocarcinoma, and Dysplasia)

A panel of circulating microRNA, whose expression level is tested in cell-free derived samples.

Sponsors & Collaborators

  • City of Hope Medical Center

    lead OTHER

Principal Investigators

  • Ajay Goel, PhD · City of Hope Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-15
Primary Completion
2024-04-24
Completion
2024-04-24

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06381583 on ClinicalTrials.gov